ANI Pharmaceuticals Inc Dossier - Source-backed chat

ANI Pharmaceuticals Inc

ANIPNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)0.64

Intrinsic Value $129.37median of 6 methods · middle span $105-$361based on filings through 30 Jun 2026

Market Price $72.65Price as of 30 Sep 2026

Significantly undervaluedIntrinsic value is 78% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+78%)

Data confidence Sign in to view data confidence

Market Cap $1.7B

Enterprise Value $1.6B

Shares Outstanding 22.8M diluted

Moat Rating Wide

Next Earnings Date6 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ANI Pharmaceuticals is successfully executing a high-margin strategic pivot from a legacy generics manufacturer into a leading rare disease-focused biopharmaceutical player. This transformation is anchored by its flagship asset, Purified Cortrophin Gel, which is projected to grow 55-65% year-over-year in 2026 to reach $540M-$575M, driving the Rare Disease segment to represent approximately 60% of total revenues. Despite near-term operational headwinds, including a minor Class II recall of Estradiol Gel and customer concentration risks, the company's robust cash generation, low net leverage of 1.3x, and a newly authorized $100M share repurchase program provide a highly favorable risk-reward profile with significant valuation upside.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$90.00

Mean target$108.38

High · most bullish analyst$121.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$100.00

Cortrophin Gel growth decelerates due to aggressive competitive pricing from Keenova's Acthar Gel or restrictive payer coverage. Additionally, generic pricing erosion intensifies, and the Estradiol Gel recall escalates into broader systemic quality control issues, depressing gross margins and limiting 2026 revenues to the low end of guidance (~$1.05 billion) with compressed EBITDA margins.

Base CaseCentral scenario

$108.38

Matches the consensus mean

ANI delivers on its raised 2026 guidance, achieving total net revenues of $1.08B to $1.14B (representing ~26% YoY growth) and adjusted non-GAAP EBITDA of $285M to $300M. Cortrophin Gel remains the primary growth engine, generating $540M to $575M, while the legacy generics business remains stable, funding the $100M share buyback program and maintaining a conservative net leverage ratio of ~1.3x.

Bull CaseUpside scenario

$124.00

Cortrophin Gel experiences accelerated adoption in underpenetrated specialties (such as nephrology, neurology, and rheumatology) and successfully expands into acute gouty arthritis flares, exceeding the high end of guidance. Concurrently, the retina franchise (Iluvien) recovers faster than expected, and the generics segment continues to deliver stable, high-margin cash flows with 15+ successful annual launches, driving total 2026 revenues above $1.14 billion and adjusted EBITDA above $300 million.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum of flagship asset Cortrophin Gel, projected to grow 55-65% YoY in 2026.
Successful strategic transformation into a high-margin rare disease company, with rare disease expected to comprise ~60% of 2026 revenues.
Robust balance sheet with $311M in cash as of Q1 2026, low net leverage of 1.3x, and a newly authorized $100M share repurchase program.

Key Investment Risks

High customer concentration, with the top three wholesale distributors accounting for 53% of 2025 revenues.
Intensifying competition in the ACTH market, primarily from Keenova Therapeutics' Acthar Gel.
Regulatory and operational risks, as highlighted by the voluntary Class II recall of Estradiol Gel in May 2026.

Thesis Invalidation Triggers

Cortrophin Gel quarterly revenue growth falling below 30% YoY.
Significant pricing pressure or restrictive formulary exclusions by major commercial payers for Cortrophin Gel.
Systemic manufacturing compliance failures leading to FDA warning letters or extended plant shutdowns.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.